Overview

A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice

Status:
Completed
Trial end date:
2016-07-27
Target enrollment:
0
Participant gender:
All
Summary
A study to understand the impact of Betmiga® on patients quality of life, satisfaction with treatment, how long patients remain on treatment, patterns of healthcare resource utilisation, and safety as prescribed by the physicians in routine clinical practice.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Astellas Pharma Europe Ltd.
Treatments:
Mirabegron
Criteria
Inclusion Criteria:

- Patients who have been diagnosed with OAB symptoms at Visit 1 of this study. OAB is
defined by the International Urogynecological Association (IUGA)/International
Continence Society (ICS) 2010 joint report as urinary urgency, with or without urinary
incontinence, usually with frequency and nocturia, with no proven infection or other
obvious pathology.

- Patients whose physician has made the decision to prescribe Betmiga® as part of
routine clinical practice and who are about to start treatment.

Exclusion Criteria:

- Patients who are currently taking Betmiga®.

- Contraindication(s) as per the Betmiga® Summary of Product Characteristics (SPC).